Investors read the deck. They do not believe the commercial story. Partners read the same pages. They see technical risk. Buyers reach for a reference frame and borrow one from the wrong adjacent category. The go-to-market is not a communications problem. It is a translation problem.
Built for life sciences and biotech CEOs. Applies to medtech founders, biopharma BD leaders, and clinical-stage commercial leads, and similar strategic leaders at commercial-stage biotechs.
Commercial narrative. Partner-ready story. Buyer reference-frame architecture. Sequencing that moves a business audience from interest to conviction.
Read the scope →Biotech companies struggle with commercial traction because scientific credibility does not translate automatically into commercial credibility. Investors, partners, and buyers read the same material and reach different conclusions. The work here rebuilds the commercial narrative, aligns the buyer reference frame, and sequences the partner conversation so that a business audience can act on the science. Output is a commercial story investors, partners, and strategic buyers will believe.
The vertical matters because the buying committee, risk language, proof standard, sales cycle, and trigger event change by category. The strategy has to reflect that reality before channels or creative are chosen.
The page identifies the real decision participants: economic buyer, evaluator, champion, operator, or referral source.
Every market has a different perceived risk: budget waste, operational failure, compliance exposure, partner credibility, or reputation.
The strategy defines which proof the buyer needs before action: numbers, process, clinical depth, technical capability, or commercial outcomes.
The page routes into the right first engagement instead of forcing a generic service conversation.
The science is not the problem. The translation between the science and the business audience is. These are the three failures that show up in every commercial-stage biotech engagement.
The scientific team is widely published. The asset is validated. The board is stacked. None of that convinces a BD leader at a strategic, a platform lead at a payer, or a partner evaluating an in-license. Those audiences read commercial proof, not scientific proof, and the two vocabularies do not overlap.
When the category is new, the buyer cannot hold it in free space. The buyer imports a reference frame from the closest adjacent incumbent, prices the asset against that frame, and mis-scopes the conversation. The commercial team wastes six months correcting a reference frame that was set in the first meeting.
The deck opens with science. The BD audience needs to see commercial logic, a buyer pathway, a reimbursement or adoption model, and a competitive moat. When the commercial story is buried in the appendix, the partner treats the asset as technical risk rather than a commercial opportunity and the conversation stalls in evaluation.
The engagement starts from the audience, not from the science. The question is not "how do we explain the asset." The question is "what does this audience need to read, in what order, to reach commercial conviction." That reframes every downstream artifact.
Problem one is credibility transfer. The solution is a commercial proof architecture that sits alongside the scientific proof and reads in a vocabulary a business audience uses. Revenue logic, buyer pathway, reimbursement framing, competitive moat, and the commercial evidence that investors and partners need to act.
Problem two is reference frames. The solution is category architecture built for the buyer, not for the team. The engagement identifies the reference frame the buyer is most likely to borrow, then sequences the conversation to migrate the buyer into a correct frame before the asset is evaluated against the wrong one.
Your go-to-market is not a communications problem. It is a translation problem. The science is credible. The translation into commercial language is what is missing.
Problem three is the partnership story. The solution is a partner-ready narrative that opens with commercial logic, leads into scientific proof as substantiation, and closes with a clear, bounded ask. Works for licensing conversations, strategic partnerships, and buy-side BD diligence.
The deliverable is a coherent commercial narrative your CEO can carry into investor conversations, your BD lead can carry into partner conversations, and your commercial team can carry into buyer conversations. One story, three audiences, sequenced for each.
One commercial narrative that reads to investors, partners, and buyers in the language each audience uses. The gap between a credible science story and a credible commercial story closes in one place, not three.
of the B2B buying journey is complete before the buyer ever contacts a vendor. In life sciences, HCPs, payers, and value analysis committees are reading independently long before the regulatory milestone.
Gartner · Future of B2B Sales · 2024
person buying committee with ten or more interactions, on average, before a B2B decision. Medtech and biopharma committees are heavier still, because clinical, payer, and operational sign-off all sit in different rooms.
McKinsey & Company · B2B Pulse Survey · 2024
match rate between how vendors describe themselves and how buyers actually experience the product. Life sciences vendors are not exempt. The commercial story is talking past the audience that signs.
TrustRadius · B2B Buying Disconnect · 2023
The three numbers describe the life sciences commercial gap. The clinical story is strong. The commercial narrative is absent from the rooms where the indication, the label, and the formulary are decided. Most commercial-stage biotech and medtech companies are not measuring the gap.
No invented benchmarks. Every line in the table below has a publisher, a year, and a public URL in the citations section at the bottom of this page.
| Source | Year | Finding relevant to Bay Area life sciences commercialization |
|---|---|---|
| Gartner · Future of B2B Sales | 2024 | Approximately 70 percent of the buying journey is complete before vendor contact. HCPs, KOLs, and payers form a position from public materials long before the rep call. |
| McKinsey · B2B Pulse Survey | 2024 | Average ten-person buying committee with ten or more interactions. Value analysis committees in medtech sit on top of that baseline, not under it. |
| Forrester · B2B Buying Group Engagement | 2024 | Buying-group engagement is a stronger leading indicator than lead volume. Demand units, not MQLs, predict commercial outcomes in committee-led categories. |
| TrustRadius · B2B Buying Disconnect | 2023 | 38 percent match rate between vendor self-description and buyer experience. Life sciences vendors over-index on mechanism, under-index on commercialization signal. |
| HubSpot · State of Marketing | 2024 | Top B2B sites publish more specific buyer-question answers than competitors. Most biotech and medtech sites still default to investor and scientific audiences. |
"Buying-group engagement is a stronger leading indicator of revenue than individual lead volume. The teams that win in committee-led categories measure demand units and account-level signal, not MQL counts."Forrester · B2B Buying Group Engagement · 2024
The science is usually credible. The commercial story is not legible to the audience that writes the checks. Investors read the deck and see a research project. Partners read the deck and see technical risk. Buyers read the deck and borrow a reference frame from a wrong adjacent category. The problem is translation, not science, and it is solved by rebuilding the commercial narrative for a business audience.
Commercial-stage biotech, medtech, and biopharma companies with a validated scientific asset and a commercial motion that has outgrown founder-led conversations. Representative clients include therapeutics companies preparing partnership conversations, medtech founders heading into commercial launch, and diagnostics companies in reimbursement and payer strategy. Not pre-asset research groups or academic spinouts without a defined commercial path.
Three recurring patterns. Technical credibility does not transfer to commercial credibility. Buyers borrow reference frames from wrong adjacent incumbents and mis-price the asset. Partnership and licensing conversations stall because the commercial story is not legible to a business audience. The engagement rebuilds the commercial narrative so the business audience can act on it.
The work is commercial translation, not scientific authoring. Your team owns the science. The engagement translates the science into a commercial narrative that investors, partners, and buyers will act on. Prior engagements cover therapeutics, diagnostics, medtech devices, and platform biology. The methodology is portable across therapeutic areas because the commercial translation problem is structurally the same.
Scientific communications firms write for a scientific audience. The work here is the opposite. It translates the science into a commercial narrative for investors, partners, and strategic buyers who do not read journals. The output is a commercial story, a partner-ready narrative, a reference-frame architecture for buyers, and the sequencing that moves a business audience from interest to conviction.
The primary gate is the dedicated life sciences engagement at /for/life-sciences, built for commercial-stage biotech and life sciences CEOs. If the problem is broader than commercial translation, the Marketing Strategy Diagnostic at $5,000 covers positioning, packaging, go-to-market, and demand generation in 10 business days. Both produce a commercial narrative your investors, partners, and buyers can act on.
The pipeline work runs on indication-specific buyer education, not label claims. Gartner's 2024 Future of B2B Sales research finds that approximately 70 percent of the buying journey is complete before vendor contact, so the commercial audience is already reading. The engagement documents HCP and KOL reference frames, payer and value analysis committee evidence requirements, and a sequenced narrative that is accurate on label status while still establishing commercial conviction. Pre-approval pipeline is built in disclosure-compliant language, not in marketing aspiration.
Value analysis committees do not buy on clinical signal alone. McKinsey's 2024 B2B Pulse Survey documents an average ten-person buying committee with ten or more interactions, and medtech committees are heavier still. Forrester's 2024 research on buying-group engagement finds that committee-level engagement is a stronger leading indicator than individual lead volume. The remediation maps each committee role, the evidence each role requires, and the sequencing that allows the champion to carry the file. Most medtech launches stall because the commercial materials address only the clinician.
Lead volume is not a credible measure in life sciences. TrustRadius's 2023 B2B Buying Disconnect study reports a 38 percent match rate between how vendors describe themselves and how buyers experience the product, and life sciences vendors are not exempt. The measurement framework tracks buying-committee engagement depth, indication-specific reference-frame adoption, and movement of named accounts through documented commercialization stages. HubSpot's 2024 State of Marketing data shows the highest-performing B2B sites publish more specific buyer-question answers than their competitors. That is the lagging indicator the framework is in place.
If you want a senior strategist to review your commercial direction before committing to a full engagement, the founder at stantscherenkow.com works directly with a small number of operators.
Life sciences engagement for commercial-stage biotech, medtech, and biopharma. Commercial narrative, partner-ready story, buyer reference-frame architecture, sequenced for investor, partner, and buyer conversations.
Adjacent industry: Marketing for AI companies. Applied-science GTM dynamics overlap.